Loading
Immunotherapy added to first-line chemotherapy has failed to extend survival in ovarian cancer in every large trial so far; its only win is in PD-L1-positive platinum-resistant disease.
IMagyn050 (atezolizumab), JAVELIN Ovarian 100 (avelumab), and DUO-O (durvalumab ± olaparib) showed no OS benefit in newly diagnosed disease. KEYNOTE-B96 (pembrolizumab + weekly paclitaxel) is the exception, in PD-L1-positive platinum-resistant relapse. Ovarian cancer is immunologically 'cold' with low TMB.
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
Shares PD-L1, PD-1, Immune checkpoint inhibitors.